|
Guardian Unlimited | Archive Search
tails; we still carry with us our evolutionary ascent from bacteria in the swamp. Scattered at the pathway, or docking site, known as the CCR5 receptor, by which the Aids virus enters human
http://www.guardian.co.uk ,4273,4014993,00.html
AIDS Community Health Center
Therapies for a GlaxoSmithKline CCR100136 ASCENT ñ A phase IIb, randomized, multi-center selected immunological and Pfizer UK-427,852 CCR5 inhibitor for HIV-1 experienced patients. 1027
http://www.communityhealthnet.com/research.php
GMHC: Treatment Issues
A new class drugs called CCR5 blockers are designed to keep HIV from interacting with a protein on T-cells that the virus must bind to before it can infect a cell. The drugs stick to CCR5 and
http://www.gmhc.org/healt atment/ti/ti1801.html
| 
